1-3 of 3
Mark P. Smith
Close
Sort by
Journal Articles

Impact of Treatment Regimen with Moroctocog Alfa (AF-CC) on Bleeding Frequency in Pediatric Aged Subjects with Moderately Severe to Severe Hemophilia A

Mark P. Smith, MD FRACP, FRCPA, Jeremy Rupon, MD, Yasser Wali, MD, Hala Remawi, MD, Joan Korth-Bradley, PharmD, PhD, Lynne Smith, MBA, Pablo Rendo, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 1205.
https://doi.org/10.1182/blood-2018-99-111891
Published: 2018
Journal Articles

A Post-Marketing Surveillance Study of the Safety and Efficiacy of Refacto® (Moroctocog Alfa, B-Domain Deleted Recombinant Factor VIII) (St. Louis-Derived Active Substance in the Treatment and Prevension of Bleeding Episodes in Hemophilia a Patients.

Jay M. Feingold, MD, PhD, Mark P. Smith, MD, Richard Littlewood, MD, Paul Giangrande, MD, ReFacto STL Study Group
Journal: Blood
Blood (2004) 104 (11): 4023.
https://doi.org/10.1182/blood.V104.11.4023.4023
Published: 2004
Journal Articles

Evidence for a role for Gα i1 in mediating weak agonist-induced platelet aggregation in human platelets: reduced Gα i1 expression and defective G i signaling in the platelets of a patient with a chronic bleeding disorder

Clinical Trials & Observations
Yatin M. Patel, Kirti Patel, Salman Rahman, Mark P. Smith, Gillian Spooner, Rushika Sumathipala, Michael Mitchell, Geraldine Flynn, Alexandra Aitken, Geoffrey Savidge
Journal: Blood
Blood (2003) 101 (12): 4828–4835.
https://doi.org/10.1182/blood-2002-10-3080
Published: 2003